Lung Cancer Trial, Recruiting NCT05526534 Sponsor: Sichuan Cancer Hospital and Research Institute Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT05526534
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 90 who have been diagnosed with a gynecological tumour (either non-cancerous or cancerous) and are scheduled for surgery expected to last at least 2 hours
  • People who have had a chest CT scan (a type of detailed X-ray) within the week before their planned surgery
  • People who meet at least one of the following conditions:
    • A score of 45 points or more on a specific breathing risk assessment tool called ARRSPC (confirm with trial site)
    • A Body Mass Index (BMI) of 30 or above (considered obese range)
    • A diagnosis of moderate to severe asthma
    • A diagnosis of moderate to severe chronic obstructive pulmonary disease (COPD), a long-term lung condition
    • A smoking history of 20 packs per year or more (for example, one pack a day for 20 years)

Who may not be able to join:

  • People who have cancer that has spread to the lungs, or who have a primary cancer that started in the lungs
  • People who have previously had lung surgery or radiation treatment to the lungs
  • People whose planned surgery involves removing a section of the bowel

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dengfeng Wang, M.D., Sichuan Cancer Hospital and Research Institute

Phone: +86 159 82222707

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Sichuan Cancer Hospital and Research Institute
Registry
ClinicalTrials.gov
Start date
1 November 2022
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Postoperative pulmonary complication

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov